Novavax, Inc. (NASDAQ:NVAX) Receives Average Recommendation of "Hold" from Analysts

Shares of Novavax, Inc. (NASDAQ:NVAX - Get Free Report) have received a consensus rating of "Hold" from the seven ratings firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $18.00.

Several research firms have issued reports on NVAX. TD Cowen upgraded Novavax to a "hold" rating in a research report on Thursday, February 27th. BTIG Research initiated coverage on shares of Novavax in a research report on Friday, February 28th. They issued a "buy" rating and a $19.00 target price on the stock.

Institutional Trading of Novavax

Several large investors have recently modified their holdings of NVAX. GF Fund Management CO. LTD. bought a new position in Novavax during the 4th quarter worth approximately $27,000. Spire Wealth Management bought a new position in Novavax in the 4th quarter worth approximately $29,000. New Age Alpha Advisors LLC acquired a new position in shares of Novavax during the fourth quarter valued at $35,000. KBC Group NV lifted its stake in shares of Novavax by 97.0% in the 4th quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company's stock worth $64,000 after acquiring an additional 3,917 shares during the period. Finally, TigerOak Management L.L.C. acquired a new stake in Novavax in the fourth quarter worth approximately $86,000. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Novavax Trading Down 5.7 %

NASDAQ:NVAX opened at $6.67 on Monday. The firm has a market cap of $1.07 billion, a PE ratio of -2.95, a price-to-earnings-growth ratio of 2.85 and a beta of 3.15. The stock has a fifty day moving average price of $7.13 and a 200 day moving average price of $8.32. Novavax has a 12-month low of $4.10 and a 12-month high of $23.86.

Novavax (NASDAQ:NVAX - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.24. The company had revenue of $88.31 million during the quarter, compared to analyst estimates of $85.48 million. During the same quarter in the prior year, the company earned ($1.44) EPS. Equities analysts forecast that Novavax will post -1.46 EPS for the current year.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.